PE20230830A1 - Formulaciones farmaceuticas de acetato de abiraterona y niraparib - Google Patents
Formulaciones farmaceuticas de acetato de abiraterona y niraparibInfo
- Publication number
- PE20230830A1 PE20230830A1 PE2022002554A PE2022002554A PE20230830A1 PE 20230830 A1 PE20230830 A1 PE 20230830A1 PE 2022002554 A PE2022002554 A PE 2022002554A PE 2022002554 A PE2022002554 A PE 2022002554A PE 20230830 A1 PE20230830 A1 PE 20230830A1
- Authority
- PE
- Peru
- Prior art keywords
- abiraterone acetate
- niraparib
- pharmaceutical formulations
- composition
- glidant
- Prior art date
Links
- 229960004103 abiraterone acetate Drugs 0.000 title abstract 2
- UVIQSJCZCSLXRZ-UBUQANBQSA-N abiraterone acetate Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CC[C@@H](CC4=CC[C@H]31)OC(=O)C)C=C2C1=CC=CN=C1 UVIQSJCZCSLXRZ-UBUQANBQSA-N 0.000 title abstract 2
- 229950011068 niraparib Drugs 0.000 title abstract 2
- PCHKPVIQAHNQLW-CQSZACIVSA-N niraparib Chemical compound N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCCNC1 PCHKPVIQAHNQLW-CQSZACIVSA-N 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 102000001307 androgen receptors Human genes 0.000 abstract 2
- 108010080146 androgen receptors Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000007884 disintegrant Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000008187 granular material Substances 0.000 abstract 1
- 239000008202 granule composition Substances 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000006186 oral dosage form Substances 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 239000000080 wetting agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Epoxy Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Referido a una composicion en granulos que comprende acetato de abiraterona, monohidrato de tosilato de niraparib y un transportador farmaceuticamente aceptable; en donde el citado transportador comprende un agente humectante, un diluyente, un disgregante; opcionalmente un deslizante, lubricante y aglutinante. Dichos granulos tienen una distribucion del tamano de particula con un d50 de aproximadamente 200 a aproximadamente 500 µm. Tambien se refiere a una forma de dosificacion oral de dicha composicion en granulos y un proceso de preparacion; siendo util en tratamiento de una enfermedad o afeccion relacionada con el receptor de androgenos (AR), en particular el cancer, mas en particular el cancer de prostata
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20173749 | 2020-05-08 | ||
| US202163142919P | 2021-01-28 | 2021-01-28 | |
| US202163174282P | 2021-04-13 | 2021-04-13 | |
| PCT/EP2021/062188 WO2021224471A1 (en) | 2020-05-08 | 2021-05-07 | Pharmaceutical formulations of abiraterone acetate and niraparib |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20230830A1 true PE20230830A1 (es) | 2023-05-19 |
Family
ID=75888052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022002554A PE20230830A1 (es) | 2020-05-08 | 2021-05-07 | Formulaciones farmaceuticas de acetato de abiraterona y niraparib |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20230226080A1 (es) |
| EP (3) | EP4146209A1 (es) |
| JP (3) | JP2023524794A (es) |
| KR (3) | KR20230008780A (es) |
| CN (3) | CN115515584A (es) |
| AU (3) | AU2021267146A1 (es) |
| BR (3) | BR112022021732A2 (es) |
| CA (3) | CA3177137A1 (es) |
| CR (1) | CR20220588A (es) |
| EC (1) | ECSP22085983A (es) |
| IL (3) | IL297990A (es) |
| MX (3) | MX2022014004A (es) |
| PE (1) | PE20230830A1 (es) |
| TW (3) | TW202207925A (es) |
| UY (3) | UY39203A (es) |
| WO (3) | WO2021224471A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023148345A1 (en) * | 2022-02-04 | 2023-08-10 | Janssen Pharmaceutica Nv | Niraparib and abiraterone acetate plus prednisone to improve clinical outcomes in patients with metastatic castration-resistant prostate cancer and hrr alterations |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0633893T3 (da) | 1992-03-31 | 2000-04-17 | Btg Int Ltd | 17-Substituerede steroider, der er nyttige ved cancerbehandling |
| SI2805945T1 (sl) | 2007-01-10 | 2019-09-30 | Msd Italia S.R.L. | Amid substituirani indazoli, kot inhibitorji poli(ADP-riboza)polimeraze(PARP) |
| RU2495035C2 (ru) | 2008-01-08 | 2013-10-10 | Мерк Шарп Энд Домэ Лтд | Фармацевтически приемлемые соли 2-{4-[(3s)-пиперидин-3-ил]фенил}-2н-индазол-7-карбоксамида |
| CN102743393A (zh) * | 2012-07-27 | 2012-10-24 | 海南盛科生命科学研究院 | 一种含有醋酸阿比特龙的药物组合物及制备工艺 |
| WO2015032873A1 (en) * | 2013-09-06 | 2015-03-12 | Synthon B.V. | High-load pharmaceutical compositions comprising abiraterone acetate |
| WO2016001208A1 (en) * | 2014-06-30 | 2016-01-07 | Galenicum Health S.L. | Stable pharmaceutical compositions in the form of immediate release tablets |
| TN2018000318A1 (en) * | 2014-09-18 | 2020-01-16 | Iceutica Inc | Abiraterone acetate formulation and methods of use. |
| BR112019020211A2 (pt) | 2017-03-27 | 2020-04-22 | Tesaro Inc | composições de niraparib |
| JOP20190244A1 (ar) * | 2017-04-13 | 2019-10-13 | Janssen Pharmaceutica Nv | تركيبة علاجية لسرطان البروستاتا |
| CA3076907A1 (en) * | 2017-09-26 | 2019-04-04 | Tesaro, Inc. | Niraparib formulations |
| BR112020007090A2 (pt) * | 2017-10-11 | 2020-09-24 | Janssen Oncology, Inc. | métodos de tratamento de câncer de próstata mediante a administração de acetato de abiraterona mais prednisona com terapia de supressão androgênica |
| WO2019206472A1 (en) * | 2018-04-26 | 2019-10-31 | Synthon B.V. | Tablet compositions comprising abiraterone acetate |
| ES2967517T3 (es) | 2018-10-03 | 2024-04-30 | Tesaro Inc | Sales de niraparib |
-
2021
- 2021-05-07 TW TW110116506A patent/TW202207925A/zh unknown
- 2021-05-07 AU AU2021267146A patent/AU2021267146A1/en active Pending
- 2021-05-07 CN CN202180033488.6A patent/CN115515584A/zh active Pending
- 2021-05-07 WO PCT/EP2021/062188 patent/WO2021224471A1/en active Application Filing
- 2021-05-07 MX MX2022014004A patent/MX2022014004A/es unknown
- 2021-05-07 CN CN202180033482.9A patent/CN115515583A/zh active Pending
- 2021-05-07 MX MX2022014005A patent/MX2022014005A/es unknown
- 2021-05-07 CA CA3177137A patent/CA3177137A1/en active Pending
- 2021-05-07 IL IL297990A patent/IL297990A/en unknown
- 2021-05-07 EP EP21724665.1A patent/EP4146209A1/en active Pending
- 2021-05-07 BR BR112022021732A patent/BR112022021732A2/pt unknown
- 2021-05-07 KR KR1020227042483A patent/KR20230008780A/ko active Search and Examination
- 2021-05-07 CA CA3177123A patent/CA3177123A1/en active Pending
- 2021-05-07 CN CN202180033483.3A patent/CN115551506A/zh active Pending
- 2021-05-07 WO PCT/EP2021/062180 patent/WO2021224467A1/en unknown
- 2021-05-07 IL IL297984A patent/IL297984A/en unknown
- 2021-05-07 UY UY0001039203A patent/UY39203A/es unknown
- 2021-05-07 JP JP2022567451A patent/JP2023524794A/ja active Pending
- 2021-05-07 TW TW110116507A patent/TW202211921A/zh unknown
- 2021-05-07 JP JP2022567447A patent/JP2023525026A/ja active Pending
- 2021-05-07 AU AU2021269115A patent/AU2021269115A1/en active Pending
- 2021-05-07 UY UY0001039201A patent/UY39201A/es unknown
- 2021-05-07 TW TW110116509A patent/TW202207926A/zh unknown
- 2021-05-07 AU AU2021266409A patent/AU2021266409A1/en active Pending
- 2021-05-07 US US17/998,202 patent/US20230226080A1/en active Pending
- 2021-05-07 KR KR1020227042489A patent/KR20230008782A/ko active Search and Examination
- 2021-05-07 EP EP21725101.6A patent/EP4146211A1/en active Pending
- 2021-05-07 BR BR112022022590A patent/BR112022022590A2/pt unknown
- 2021-05-07 US US17/998,204 patent/US20230226081A1/en active Pending
- 2021-05-07 BR BR112022022534A patent/BR112022022534A2/pt unknown
- 2021-05-07 EP EP21725098.4A patent/EP4146210A1/en active Pending
- 2021-05-07 IL IL297991A patent/IL297991A/en unknown
- 2021-05-07 US US17/998,198 patent/US20230218640A1/en active Pending
- 2021-05-07 UY UY0001039204A patent/UY39204A/es unknown
- 2021-05-07 KR KR1020227042495A patent/KR20230008783A/ko active Search and Examination
- 2021-05-07 CA CA3177094A patent/CA3177094A1/en active Pending
- 2021-05-07 CR CR20220588A patent/CR20220588A/es unknown
- 2021-05-07 WO PCT/EP2021/062186 patent/WO2021224469A1/en unknown
- 2021-05-07 PE PE2022002554A patent/PE20230830A1/es unknown
- 2021-05-07 JP JP2022567542A patent/JP2023524808A/ja active Pending
- 2021-05-07 MX MX2022014003A patent/MX2022014003A/es unknown
-
2022
- 2022-11-08 EC ECSENADI202285983A patent/ECSP22085983A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6797980B2 (ja) | ルカパリブの高投与力価錠剤 | |
| KR102464646B1 (ko) | (r)-2-아미노-3-페닐프로필 카바메이트의 제제 | |
| CN103550165B (zh) | 一种含有利伐沙班的药物组合物及其制备方法 | |
| NZ734446A (en) | Pharmaceutical formulations of bruton’s tyrosine kinase inhibtor | |
| NZ599430A (en) | A drug delivery system for the prevention of cerebral vasospasm | |
| CN105250231B (zh) | 一种含有依托考昔的药物组合物及其制备方法 | |
| CN108201536A (zh) | 一种奥拉帕尼口服缓控释药物组合物及其用途 | |
| CN104434931A (zh) | 含替格瑞洛和阿司匹林的复方口服固体剂及其制备方法 | |
| KR20080032209A (ko) | 사이클로옥시지네이즈 효소 억제제를 구성하는 새로운형태의 약학적 변형된 용출 용량형 조성물 | |
| MX2008015253A (es) | Formulaciones de liberacion controlada. | |
| PE20230830A1 (es) | Formulaciones farmaceuticas de acetato de abiraterona y niraparib | |
| JPH05194238A (ja) | Ｗｉｎ４９５９６−フィナステリドの使用方法及び組成物 | |
| EP3150201A1 (en) | Composite preparation comprising 5- -reductase inhibitor-containing film coating layer, and method for producing the composite preparation | |
| CN110062628A (zh) | 一种瑞卡帕布口服缓控释药物组合物及其用途 | |
| CN108201535A (zh) | 一种维利帕尼缓控释药物组合物及其用途 | |
| CN103717209A (zh) | 速释的含普拉格雷的稳定的口服药物组合物 | |
| KR20220125232A (ko) | Ahr 억제제 및 이의 용도 | |
| CN102764254B (zh) | 一种左乙拉西坦药物组合物及其制备方法 | |
| CN109125270B (zh) | 一种固体制剂及其制备方法 | |
| CN102198113A (zh) | 一种富马酸喹硫平缓释片制备工艺 | |
| JP2020176090A (ja) | ダサチニブ無水物を含有する固形製剤の製造方法 | |
| JP2019147798A (ja) | ダサチニブ無水物の結晶形態が安定に維持された固形製剤の製造方法 | |
| ES2898456T3 (es) | Composición farmacéutica que comprende un agente antifúngico triazol y método de preparación de la misma | |
| JP2019089758A (ja) | セレコキシブ含有錠剤における溶出性の改善方法 | |
| CN104306345B (zh) | 一种布南色林的口服缓释制剂 |